Add BrightSurf on Google Email

University College Dublin researcher receives award to explore the disruptive power of macromolecular crowding in cell culture systems

A University College Dublin researcher has received a European Research Council Proof of Concept grant to investigate the disruptive power of macromolecular crowding in cell culture systems. The project aims to develop novel approaches for regenerative medicine by accelerating tissue development and improving therapeutic potential.

NIH spent $950M for basic or applied research leading to patents providing market exclusivity for drugs approved 2010-19

The National Institutes of Health (NIH) invested approximately $164 billion in project funding prior to first drug approval, with only 0.59% ($0.95/$164 billion) associated with patents providing market exclusivity. This research highlights the limited public interest protections for NIH-funded research on new drugs approved between 20...

SourceBentley University·JournalPLOS ONE·TypeObservational study·DateJul 26, 2023

NIH spent $8.1B for phased clinical trials of drugs approved 2010-19, ~10% of reported industry spending

A new study by Bentley University reveals the NIH's significant investment in pharmaceutical innovation, with $8.1 billion spent on phased clinical trials between 2010-19. The funding represents only ~10% of reported industry costs for these trials, highlighting the public sector's limited contribution to drug development.

SourceBentley University·JournalJAMA Health Forum·TypeObservational study·DateJul 14, 2023

University hospitals and Case Western Reserve University research teams receive Collaborative Science Pilot Awards

Three University Hospitals and Case Western Reserve University research teams received $50,000 Collaborative Science Pilot Awards to explore innovative research projects. The awards aim to increase competitiveness and capacity for major external funding opportunities in key areas such as cancer, brain health and genetics.

Taming a frenzied immune system

UofL researchers, led by Jun Yan, will investigate the causes of immune system overresponse in COVID-19 patients, leading to severe lung disease and death. They aim to develop methods to predict, prevent or control this response with potential treatments for other conditions.

You’ve got some nerve

Researchers developed a new metric to analyze the relationship between nerve density and oral cancer progression. Normalized nerve density was found to be associated with poor survival rates for patients with tongue cancer, highlighting its potential as a tool for identifying aggressive tumors.

SourceMichigan Medicine - University of Michigan·JournalClinical Cancer Research·TypeExperimental study·DateMay 16, 2023

The Texas Heart Institute and The University of Texas at Austin awarded a National Institutes of Health grant to develop injectable hydrogel electrodes to prevent ventricular arrhythmias

The Texas Heart Institute and The University of Texas at Austin receive a four-year, $2.37 million NIH grant to develop injectable hydrogel electrodes for preventing and managing ventricular arrhythmias. Researchers have already demonstrated the feasibility of pacing the heart using the hydrogel in a porcine model.

Study identifies genetic mutations that contribute to adult epilepsy

Researchers have identified 11 somatic mutations in the RAS/MAPK pathway that contribute to treatment-resistant adult epilepsy, suggesting the potential for repurposed anti-cancer agents as new treatments. This study provides insight into the genetic mechanisms underlying this form of epilepsy and opens up new avenues for targeted ther...

SourceMass General Brigham·JournalJournal of the American Medical Association·TypeCase study·DateMay 1, 2023

Bentley University study shows NIH investment in new drug approvals is comparable to investment by pharmaceutical industry

A Bentley University study shows that the National Institutes of Health (NIH) invests similarly to the pharmaceutical industry in bringing new drugs to market. The NIH spent $187 billion on research related to FDA-approved drugs between 2010-2019, with an average investment per approved drug of $1.7 billion.

SourceBentley University·JournalJAMA Health Forum·DateApr 28, 2023

Wayne State researcher receives $1.95 million NIH grant to study impact of inositol homeostasis on essential cellular functions

A Wayne State University researcher has received a $1.95 million grant to study the regulation of inositol synthesis and its effects on essential cellular functions in human cells. The study aims to identify mechanisms that regulate inositol synthesis and determine its impact on cell signaling and metabolism.

Albert Einstein College of Medicine and Montefiore Health System awarded $30 million from NIH to support its Institute for Clinical and Translational Research

The Albert Einstein College of Medicine and Montefiore Health System have received a seven-year, $30 million grant from the National Institutes of Health to continue supporting the Harold and Muriel Block Institute for Clinical and Translational Research. The grant will advance translational science and health equity by accelerating th...

Richard McIndoe, PhD, will direct Coordinating Unit for new, national research initiative in diabetes, obesity

Richard McIndoe is leading a national research initiative to advance understanding of diabetes and obesity through the National Centers for Metabolic Phenotyping in Live Models of Obesity and Diabetes (MPMOD). The MPMOD initiative provides access to advanced testing services, including bariatric surgery on mice, to enable new insights ...

Mass General Brigham study finds virtual care team strategy improved treatment for heart failure patients

A virtual care team consisting of physicians and pharmacists improved the adoption of life-saving therapies in patients with heart failure, leading to increased use of evidence-based treatments and better patient outcomes. The strategy was safe and effective, with comparable length of stay and safety events between the groups.

SourceMass General Brigham·JournalJournal of the American College of Cardiology·TypeRandomized controlled/clinical trial·DateMar 6, 2023